Pieris Historical Income Statement

PIRS Stock

USD 16.77 0.84 5.27%

Historical analysis of Pieris Pharmaceuticals income statement accounts such as Total Revenue of 24.3 M, Gross Profit of 958.5 K, Other Operating Expenses of 47.4 M or Research Development of 34.9 M can show how well Pieris Pharmaceuticals performed in making a profits. Evaluating Pieris Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Pieris Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Pieris Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pieris Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.

About Pieris Income Statement Analysis

Pieris Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Pieris Pharmaceuticals shareholders. The income statement also shows Pieris investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Pieris Pharmaceuticals Income Statement Chart

At this time, Pieris Pharmaceuticals' Interest Expense is comparatively stable compared to the past year. Total Other Income Expense Net is likely to gain to about 5.5 M in 2024, whereas Selling General Administrative is likely to drop slightly above 13.5 M in 2024.

Selling General Administrative Selling And Marketing Expenses Total Revenue Other Operating Expenses Reconciled Depreciation

Total Revenue

Total revenue comprises all receipts Pieris Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Pieris Pharmaceuticals. It is also known as Pieris Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Pieris Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Pieris Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.At this time, Pieris Pharmaceuticals' Interest Expense is comparatively stable compared to the past year. Total Other Income Expense Net is likely to gain to about 5.5 M in 2024, whereas Selling General Administrative is likely to drop slightly above 13.5 M in 2024.

	2021	2022	2023	2024 (projected)
Net Interest Income	4K	721K	1.7M	936.8K
Interest Income	4K	721K	1.7M	1.8M

Net Interest Income Interest Income

Pieris Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Cost Of Revenue	Non Recurring	Non Operating Income Net Other	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.72	0.6	-0.19	0.63	-0.02	0.77	-0.83	-0.77	0.84	-0.75	0.77	-0.79	0.66	-0.78	0.12	-0.8	0.27	0.29	0.32	-0.34	0.25	0.31	0.97
Interest Expense	0.72		0.57	-0.74	0.56	0.04	0.64	-0.68	-0.58	0.59	-0.56	0.64	-0.58	0.79	-0.58	0.68	-0.64	0.22	0.73	0.67	-0.34	0.6	0.52	0.84
Selling General Administrative	0.6	0.57		-0.2	0.78	0.02	0.94	-0.85	-0.87	0.82	-0.86	0.94	-0.87	0.42	-0.88	0.17	-0.88	0.63	0.26	0.16	-0.12	0.57	0.66	0.61
Selling And Marketing Expenses	-0.19	-0.74	-0.2		-0.27	0.25	-0.23	0.23	0.18	-0.15	0.15	-0.23	0.17	-0.38	0.19	-0.93	0.25	-0.23	-0.8	-0.51	0.2	-0.59	-0.36	-0.41
Total Revenue	0.63	0.56	0.78	-0.27		-0.1	0.88	-0.66	-0.66	0.85	-0.66	0.88	-0.64	0.42	-0.64	0.27	-0.66	0.66	0.44	0.23	-0.24	0.7	0.79	0.66
Gross Profit	-0.02	0.04	0.02	0.25	-0.1		-0.02	-0.09	-0.05	0.05	-0.06	-0.02	-0.01	0.38	0.0	-0.29	0.01	-0.55	-0.25	0.39	0.1	-0.18	-0.13	-0.09
Other Operating Expenses	0.77	0.64	0.94	-0.23	0.88	-0.02		-0.92	-0.93	0.95	-0.92	1.0	-0.92	0.54	-0.91	0.18	-0.93	0.59	0.34	0.3	-0.32	0.58	0.68	0.77
Operating Income	-0.83	-0.68	-0.85	0.23	-0.66	-0.09	-0.92		0.99	-0.92	0.98	-0.92	0.98	-0.66	0.97	-0.11	0.98	-0.36	-0.23	-0.4	0.39	-0.41	-0.47	-0.82
Ebit	-0.77	-0.58	-0.87	0.18	-0.66	-0.05	-0.93	0.99		-0.91	1.0	-0.93	0.99	-0.56	0.99	-0.06	0.99	-0.42	-0.17	-0.3	0.38	-0.41	-0.48	-0.75
Research Development	0.84	0.59	0.82	-0.15	0.85	0.05	0.95	-0.92	-0.91		-0.91	0.95	-0.9	0.61	-0.88	0.04	-0.9	0.45	0.19	0.33	-0.4	0.49	0.58	0.8
Ebitda	-0.75	-0.56	-0.86	0.15	-0.66	-0.06	-0.92	0.98	1.0	-0.91		-0.92	0.99	-0.54	0.99	-0.04	0.98	-0.41	-0.15	-0.3	0.39	-0.4	-0.48	-0.72
Total Operating Expenses	0.77	0.64	0.94	-0.23	0.88	-0.02	1.0	-0.92	-0.93	0.95	-0.92		-0.92	0.54	-0.91	0.18	-0.93	0.59	0.34	0.3	-0.32	0.58	0.68	0.77
Income Before Tax	-0.79	-0.58	-0.87	0.17	-0.64	-0.01	-0.92	0.98	0.99	-0.9	0.99	-0.92		-0.51	1.0	-0.06	1.0	-0.44	-0.16	-0.24	0.32	-0.35	-0.42	-0.77
Total Other Income Expense Net	0.66	0.79	0.42	-0.38	0.42	0.38	0.54	-0.66	-0.56	0.61	-0.54	0.54	-0.51		-0.48	0.25	-0.53	-0.15	0.38	0.88	-0.55	0.46	0.43	0.7
Net Income	-0.78	-0.58	-0.88	0.19	-0.64	0.0	-0.91	0.97	0.99	-0.88	0.99	-0.91	1.0	-0.48		-0.08	1.0	-0.46	-0.18	-0.21	0.29	-0.35	-0.42	-0.76
Income Tax Expense	0.12	0.68	0.17	-0.93	0.27	-0.29	0.18	-0.11	-0.06	0.04	-0.04	0.18	-0.06	0.25	-0.08		-0.14	0.3	0.93	0.42	-0.1	0.56	0.39	0.35
Net Income From Continuing Ops	-0.8	-0.64	-0.88	0.25	-0.66	0.01	-0.93	0.98	0.99	-0.9	0.98	-0.93	1.0	-0.53	1.0	-0.14		-0.47	-0.24	-0.27	0.31	-0.39	-0.45	-0.79
Cost Of Revenue	0.27	0.22	0.63	-0.23	0.66	-0.55	0.59	-0.36	-0.42	0.45	-0.41	0.59	-0.44	-0.15	-0.46	0.3	-0.47		0.35	-0.3	0.2	0.4	0.47	0.32
Non Recurring	0.29	0.73	0.26	-0.8	0.44	-0.25	0.34	-0.23	-0.17	0.19	-0.15	0.34	-0.16	0.38	-0.18	0.93	-0.24	0.35		0.51	-0.2	0.58	0.5	0.5
Non Operating Income Net Other	0.32	0.67	0.16	-0.51	0.23	0.39	0.3	-0.4	-0.3	0.33	-0.3	0.3	-0.24	0.88	-0.21	0.42	-0.27	-0.3	0.51		-0.59	0.47	0.39	0.42
Tax Provision	-0.34	-0.34	-0.12	0.2	-0.24	0.1	-0.32	0.39	0.38	-0.4	0.39	-0.32	0.32	-0.55	0.29	-0.1	0.31	0.2	-0.2	-0.59		-0.53	-0.51	-0.36
Interest Income	0.25	0.6	0.57	-0.59	0.7	-0.18	0.58	-0.41	-0.41	0.49	-0.4	0.58	-0.35	0.46	-0.35	0.56	-0.39	0.4	0.58	0.47	-0.53		0.95	0.38
Net Interest Income	0.31	0.52	0.66	-0.36	0.79	-0.13	0.68	-0.47	-0.48	0.58	-0.48	0.68	-0.42	0.43	-0.42	0.39	-0.45	0.47	0.5	0.39	-0.51	0.95		0.4
Reconciled Depreciation	0.97	0.84	0.61	-0.41	0.66	-0.09	0.77	-0.82	-0.75	0.8	-0.72	0.77	-0.77	0.7	-0.76	0.35	-0.79	0.32	0.5	0.42	-0.36	0.38	0.4

Click cells to compare fundamentals

Pieris Pharmaceuticals Account Relationship Matchups

Pieris Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.0M	2.1M	2.4M	2.8M	1.9M	1.2M
Interest Expense	1.7M	3.1M	6.1M	10.2M	11.7M	12.3M
Selling General Administrative	18.4M	16.7M	16.6M	16.4M	16.9M	13.5M
Total Revenue	46.3M	29.3M	31.4M	25.9M	42.8M	24.3M
Gross Profit	(8.7M)	(17.2M)	29.1M	23.1M	1.0M	958.6K
Other Operating Expenses	73.4M	63.2M	79.6M	61.2M	72.6M	47.4M
Operating Income	(27.2M)	(33.9M)	(51.8M)	(43.5M)	(29.8M)	(31.2M)
Ebit	(27.2M)	(33.7M)	(45.7M)	(33.3M)	(24.7M)	(25.9M)
Research Development	55.0M	46.5M	66.7M	53.0M	41.8M	34.9M
Ebitda	(26.1M)	(31.6M)	(43.4M)	(30.5M)	(22.8M)	(23.9M)
Total Operating Expenses	73.4M	63.2M	79.6M	61.2M	72.6M	47.4M
Income Before Tax	(25.5M)	(37.1M)	(45.7M)	(33.3M)	(24.5M)	(25.8M)
Total Other Income Expense Net	1.7M	(3.1M)	6.1M	10.2M	5.2M	5.5M
Net Income	(23.8M)	(37.2M)	(43.4M)	(31.3M)	(24.5M)	(25.8M)
Income Tax Expense	(1.7M)	164K	(2.4M)	(2.0M)	13.9M	14.6M
Net Income From Continuing Ops	(25.5M)	(37.2M)	(45.7M)	(33.3M)	(28.1M)	(29.5M)
Cost Of Revenue	55.0M	46.5M	2.4M	2.8M	41.8M	21.2M
Net Income Applicable To Common Shares	(26.8M)	(28.3M)	(37.2M)	(45.7M)	(41.2M)	(39.1M)
Non Operating Income Net Other	1.8M	(26K)	(3.7M)	2.4M	2.8M	2.9M
Interest Income	1.7M	511K	4K	721K	1.7M	1.8M
Net Interest Income	1.7M	511K	4K	721K	1.7M	936.8K
Reconciled Depreciation	1.0M	2.1M	2.4M	2.8M	2.6M	1.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Pieris Stock Analysis

When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pieris Historical Income Statement

About Pieris Income Statement Analysis

Pieris Pharmaceuticals Income Statement Chart

Total Revenue

Other Operating Expenses

Pieris Pharmaceuticals income statement Correlations

Pieris Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pieris Pharmaceuticals income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Pieris Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Net Income From Continuing Ops	+ 1.0	Income Before Tax
Net Income From Continuing Ops	+ 1.0	Net Income
Ebit	+ 0.99	Operating Income

Net Income From Continuing Ops	- 0.93	Total Operating Expenses
Total Operating Expenses	- 0.93	Ebit
Net Income From Continuing Ops	- 0.93	Other Operating Expenses
Ebit	- 0.93	Other Operating Expenses
Income Tax Expense	- 0.93	Selling And Marketing Expenses
Income Before Tax	- 0.92	Total Operating Expenses